Epcoritamab Monotherapy as Outpatient Treatment for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Interim Results From EPCORE NHL-6

CRS and ICANS incidence and severity were consistent with the pivotal EPCORE NHL-1 trial findings. The results support feasibility of outpatient administration and monitoring of epcoritamab in 2L+ DLBCL without mandatory hospitalization for monitoring.